ICARTAB Biomedical

iCarTAB BioMed is a clinical-stage biotechnology company based in Suzhou, China, specializing in the development of advanced chimeric antigen receptor T-cell (CAR-T) therapies and multi-specific antibodies. Founded in 2015, the company focuses on treating hematological malignancies and solid tumors by targeting antigens such as CD19, CD22, B7-H3, and BCMA. iCarTAB BioMed utilizes its proprietary iTAb platform for antibody engineering and has established manufacturing capabilities in China and Malaysia. Their pipeline includes humanized CAR-T candidates for leukemia and lymphoma, as well as innovative "off-the-shelf" CAR-Vδ1T cell therapies for solid tumors like neuroblastoma and pancreatic cancer. The company actively collaborates with academic institutions and hospitals across Asia to advance its clinical programs.